Tagged: zolucatetide

Parabilis Medicines is a clinical-stage biopharmaceutical company in Cambridge, Massachusetts building stabilized, cell-penetrant alpha-helical peptides - called Helicons - that reach intracellular and 'undruggable' protein targets out of range for traditional small molecules and biologics. Formerly FogPharma, the company's lead candidate zolucatetide (FOG-001) is the first direct inhibitor of the beta-catenin/TCF interaction driving Wnt-pathway cancers, and is heading toward a registrational Phase 3 trial in desmoid tumors. Led by CEO Mathai Mammen and founded on Gregory Verdine's stapled-peptide chemistry, Parabilis has raised more than $860M, signed an up-to-$2.3B collaboration with Regeneron, and filed to go public on Nasdaq under the ticker PBLS.